Equities

Shin Nippon Biomedical Laboratories Ltd

Shin Nippon Biomedical Laboratories Ltd

Actions
IndustrialsIndustrial Support Services
  • Price (JPY)1,532.00
  • Today's Change-8.00 / -0.52%
  • Shares traded175.90k
  • 1 Year change-45.98%
  • Beta0.1737
Data delayed at least 20 minutes, as of Mar 28 2024 06:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.

  • Revenue in JPY (TTM)26.70bn
  • Net income in JPY5.50bn
  • Incorporated1973
  • Employees1.21k
  • Location
    Shin Nippon Biomedical Laboratories Ltd28F, St Luke's Tower, 8-1, Akashi-choCHUO-KU 104-0044JapanJPN
  • Phone+81 355655001
  • Fax+81 355656160
  • Websitehttps://www.snbl.co.jp/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
2395:TYO since
announced
Transaction
value
Satsuma Pharmaceuticals IncDeal completed16 Apr 202316 Apr 2023Deal completed-47.93%202.79m
Data delayed at least 20 minutes, as of Mar 28 2024 06:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Koa Shoji Holdings Co Ltd22.27bn2.86bn34.39bn297.0012.041.569.661.5472.0972.09562.08554.930.77775.992.4274,979,020.009.977.9112.389.9330.1228.7412.8310.483.6929.240.119719.648.358.2713.9029.60-21.2615.52
Daito Pharmaceutical Co Ltd45.84bn3.39bn36.78bn1.01k10.920.71395.260.8023214.53214.532,901.183,281.780.62751.912.4745,345,200.004.516.995.869.2922.0422.717.198.831.52122.890.130917.083.772.49-22.883.437.4812.70
Fuji Pharma Co Ltd41.64bn5.06bn40.50bn1.62k7.860.94754.930.9726208.19208.191,713.271,726.700.50391.402.8225,687,230.006.124.108.905.5838.5142.4112.157.550.7165--0.394731.1715.421.5227.410.370919.045.73
Seikagaku Corp34.68bn1.31bn44.09bn976.0032.330.590415.241.2724.0024.00635.691,314.470.44311.754.3135,530,740.001.670.4381.800.479750.5255.913.771.075.44--0.0055452.20-4.002.09-40.10-10.638.400.00
Shin Nippon Biomedical Laboratories Ltd26.70bn5.50bn64.11bn1.21k11.652.128.802.40132.18132.18641.45725.030.41071.275.5522,105,960.008.469.4712.3014.3452.1950.0020.6024.390.9618--0.468723.0141.378.61-14.98--37.23--
Katakura Industries Co., Ltd.39.97bn3.05bn66.52bn1.02k20.560.834511.291.6691.8691.861,206.192,263.560.28792.264.70--2.332.353.053.3438.4537.758.098.322.57--0.110517.4416.62-2.048.0918.87-7.4610.76
ASKA Pharmaceutical Holdings Co Ltd62.03bn6.51bn68.55bn747.009.751.057.281.11230.05230.052,191.752,131.760.66821.723.4083,033,460.007.023.379.094.2548.1245.3910.505.021.96--0.143315.796.814.32-1.2112.16-13.152.71
ispace Inc1.99bn-2.52bn72.18bn216.00--19.55--36.24-33.88-33.8824.7644.550.1476--24.879,219,852.00-18.66---32.11--46.91---126.42--1.72-16.860.7317--46.74---180.75------
Eiken Chemical Co Ltd39.90bn2.95bn80.60bn754.0025.541.4915.392.0278.8378.831,067.991,355.090.60132.743.0752,923,080.004.448.835.4511.3442.6746.397.3812.162.95--0.056331.240.63964.34-7.7517.070.621615.33
Data as of Mar 28 2024. Currency figures normalised to Shin Nippon Biomedical Laboratories Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

14.14%Per cent of shares held by top holders
HolderShares% Held
Asset Management One Co., Ltd.as of 31 May 20231.64m3.93%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 29 Feb 2024776.70k1.87%
The Vanguard Group, Inc.as of 07 Mar 2024669.60k1.61%
Norges Bank Investment Managementas of 31 Dec 2023578.10k1.39%
Nomura Asset Management Co., Ltd.as of 29 Feb 2024564.90k1.36%
Goldman Sachs Asset Management Co., Ltd. (Japan)as of 31 Dec 2023399.80k0.96%
Dimensional Fund Advisors LPas of 07 Mar 2024354.30k0.85%
Daiwa Asset Management Co. Ltd.as of 29 Feb 2024347.80k0.84%
Nikko Asset Management Co., Ltd.as of 08 Mar 2024281.20k0.68%
BlackRock Fund Advisorsas of 07 Mar 2024278.70k0.67%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.